{"id":2387,"date":"2025-04-03T18:14:28","date_gmt":"2025-04-03T16:14:28","guid":{"rendered":"https:\/\/www.gruppoaq.com\/approxima-7-3-million-euro-round-closed-tax-and-accounting-due-diligence-activities-to-audit-quality\/"},"modified":"2025-04-03T18:14:28","modified_gmt":"2025-04-03T16:14:28","slug":"approxima-7-3-million-euro-round-closed-tax-and-accounting-due-diligence-activities-to-audit-quality","status":"publish","type":"post","link":"https:\/\/www.gruppoaq.com\/en\/approxima-7-3-million-euro-round-closed-tax-and-accounting-due-diligence-activities-to-audit-quality\/","title":{"rendered":"Approxima, 7.3 million euro round closed. Tax and Accounting Due Diligence activities to Audit Quality"},"content":{"rendered":"\n<p>The Italian landscape of innovative startups continues to shine with success stories that testify to the excellence of research and innovation in our country.&nbsp;<strong>Approxima Srl<\/strong>, a spin-off of the Politecnico di Milano, recently concluded a significant &#8220;series A&#8221; investment round of&nbsp;<strong>7.3 million euros<\/strong>, confirming itself as one of the most promising realities in the Italian MedTech sector.<\/p>\n\n\n\n<p>The startup, founded in 2020, specializes in the development of a minimally invasive tricuspid valve repair system for the treatment of patients with tricuspid regurgitation. An innovation that could revolutionize the therapeutic approach to this pathology, offering new hope to patients suffering from this heart condition.<\/p>\n\n\n<style>.wp-block-kadence-advancedbtn.kb-btns1085_35199a-80{gap:var(--global-kb-gap-xs, 0.5rem );justify-content:flex-start;align-items:center;}.kt-btns1085_35199a-80 .kt-button{font-weight:normal;font-style:normal;}.kt-btns1085_35199a-80 .kt-btn-wrap-0{margin-right:5px;}.wp-block-kadence-advancedbtn.kt-btns1085_35199a-80 .kt-btn-wrap-0 .kt-button{color:#555555;border-color:#555555;}.wp-block-kadence-advancedbtn.kt-btns1085_35199a-80 .kt-btn-wrap-0 .kt-button:hover, .wp-block-kadence-advancedbtn.kt-btns1085_35199a-80 .kt-btn-wrap-0 .kt-button:focus{color:#ffffff;border-color:#444444;}.wp-block-kadence-advancedbtn.kt-btns1085_35199a-80 .kt-btn-wrap-0 .kt-button::before{display:none;}.wp-block-kadence-advancedbtn.kt-btns1085_35199a-80 .kt-btn-wrap-0 .kt-button:hover, .wp-block-kadence-advancedbtn.kt-btns1085_35199a-80 .kt-btn-wrap-0 .kt-button:focus{background:#444444;}<\/style>\n<div class=\"wp-block-kadence-advancedbtn kb-buttons-wrap kb-btns1085_35199a-80\"><style>ul.menu .wp-block-kadence-advancedbtn .kb-btn1085_579fe0-62.kb-button{width:initial;}.wp-block-kadence-advancedbtn .kb-btn1085_579fe0-62.kb-button{text-transform:none;}<\/style><a class=\"kb-button kt-button button kb-btn1085_579fe0-62 kt-btn-size-standard kt-btn-width-type-auto kb-btn-global-fill  kt-btn-has-text-true kt-btn-has-svg-true  wp-block-kadence-singlebtn\" href=\"https:\/\/www.approxima.com\/\" target=\"_blank\" rel=\"noreferrer noopener\"><span class=\"kt-btn-inner-text\">visit <strong>APPROXIMA<\/strong><\/span><span class=\"kb-svg-icon-wrap kb-svg-icon-fas_link kt-btn-icon-side-right\"><svg viewBox=\"0 0 512 512\"  fill=\"currentColor\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"  aria-hidden=\"true\"><path d=\"M326.612 185.391c59.747 59.809 58.927 155.698.36 214.59-.11.12-.24.25-.36.37l-67.2 67.2c-59.27 59.27-155.699 59.262-214.96 0-59.27-59.26-59.27-155.7 0-214.96l37.106-37.106c9.84-9.84 26.786-3.3 27.294 10.606.648 17.722 3.826 35.527 9.69 52.721 1.986 5.822.567 12.262-3.783 16.612l-13.087 13.087c-28.026 28.026-28.905 73.66-1.155 101.96 28.024 28.579 74.086 28.749 102.325.51l67.2-67.19c28.191-28.191 28.073-73.757 0-101.83-3.701-3.694-7.429-6.564-10.341-8.569a16.037 16.037 0 0 1-6.947-12.606c-.396-10.567 3.348-21.456 11.698-29.806l21.054-21.055c5.521-5.521 14.182-6.199 20.584-1.731a152.482 152.482 0 0 1 20.522 17.197zM467.547 44.449c-59.261-59.262-155.69-59.27-214.96 0l-67.2 67.2c-.12.12-.25.25-.36.37-58.566 58.892-59.387 154.781.36 214.59a152.454 152.454 0 0 0 20.521 17.196c6.402 4.468 15.064 3.789 20.584-1.731l21.054-21.055c8.35-8.35 12.094-19.239 11.698-29.806a16.037 16.037 0 0 0-6.947-12.606c-2.912-2.005-6.64-4.875-10.341-8.569-28.073-28.073-28.191-73.639 0-101.83l67.2-67.19c28.239-28.239 74.3-28.069 102.325.51 27.75 28.3 26.872 73.934-1.155 101.96l-13.087 13.087c-4.35 4.35-5.769 10.79-3.783 16.612 5.864 17.194 9.042 34.999 9.69 52.721.509 13.906 17.454 20.446 27.294 10.606l37.106-37.106c59.271-59.259 59.271-155.699.001-214.959z\"\/><\/svg><\/span><\/a><\/div>\n\n\n<style>.wp-block-kadence-spacer.kt-block-spacer-1085_dda93a-04 .kt-block-spacer{height:80px;}.wp-block-kadence-spacer.kt-block-spacer-1085_dda93a-04 .kt-divider{border-top-width:1px;height:1px;border-top-color:#eee;width:80%;border-top-style:solid;}<\/style>\n<div class=\"wp-block-kadence-spacer aligncenter kt-block-spacer-1085_dda93a-04\"><div class=\"kt-block-spacer kt-block-spacer-halign-center\"><hr class=\"kt-divider\" \/><\/div><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"a-strategic-investment-in-the-future-of-health\">A strategic investment in the future of health<\/h2>\n\n\n\n<p>The round saw the participation of&nbsp;<strong>two prestigious Italian investment funds<\/strong>&nbsp;specializing in the life sciences sector:&nbsp;<strong>Enea Tech<\/strong>&nbsp;and&nbsp;<strong>Panakes Partners<\/strong>. These entities, recognized for their ability to identify and support excellence in innovation in the biomedical field, have bet on the potential of the technology developed by Approxima.<\/p>\n\n\n\n<p>Investor confidence is based on the solidity of the technological project and the potential impact it could have on the treatment of tricuspid regurgitation, a condition that affects millions of people worldwide and for which current therapeutic options present significant limitations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"approxima-s-revolutionary-technology\">Approxima&#8217;s revolutionary technology<\/h2>\n\n\n\n<p>The&nbsp;<strong>system developed by Approxima<\/strong>&nbsp;allows for the remodeling of the right ventricle through a minimally invasive beating-heart procedure, guided by imaging. This percutaneous technology directly counters the dilation of the ventricle, the primary cause of tricuspid regurgitation, offering an innovative and less invasive therapeutic approach compared to traditional surgical procedures.<\/p>\n\n\n\n<p>Currently, the company is conducting preclinical feasibility studies to demonstrate the efficacy and safety of the system in vivo. The company&#8217;s offices are located in Milan, while the firm is virtually incubated at the Bioindustry Park Silvano Fumero SpA, an ecosystem that facilitates the development of innovative enterprises in the life sciences sector.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"audit-quality-s-contribution-to-the-due-diligence\">Audit Quality&#8217;s contribution to the due diligence<\/h2>\n\n\n\n<p>A fundamental role in the success of this operation was played by&nbsp;<strong>Audit Quality S.r.l.<\/strong>, a company of the&nbsp;<strong>AQ Group<\/strong>, which assisted the investment funds in the delicate phases of Tax and Accounting Due Diligence. As pointed out by Pietro Ungari: &#8220;Together with Vincenzo Romano and our entire team, I assisted the two investment funds in the Tax and Accounting Due Diligence phases.&#8221;<\/p>\n\n\n\n<p>The Audit Quality team also carried out an important work of &#8220;fairness opinion&#8221; on the pre-money value of the company Approxima, providing an independent and professional valuation that contributed to defining the terms of the investment.<\/p>\n\n\n\n<p>This collaboration highlights the importance of a multidisciplinary approach in investment operations in innovative startups, where technical expertise is paired with financial and tax knowledge to ensure the success of the operation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-value-of-innovation-in-the-medtech-sector\">The value of innovation in the MedTech sector<\/h2>\n\n\n\n<p>Approxima&#8217;s success represents a virtuous example of how innovation in the biomedical sector can attract significant investment, creating not only economic but also social value. The technology developed by the Milanese startup could indeed improve the quality of life for numerous patients, offering less invasive and more effective therapeutic solutions.<\/p>\n\n\n\n<p>The 7.3 million euro investment round will allow Approxima to accelerate the clinical development of its technology, bringing closer the moment when it can be available to patients. This type of transaction also confirms the growing interest of investors in the Italian MedTech sector, characterized by high research quality and significant growth potential.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"future-prospects-for-approxima\">Future prospects for Approxima<\/h2>\n\n\n\n<p>With this major funding, Approxima will be able to intensify research and development activities, complete preclinical studies, and prepare for subsequent phases of clinical trials. The road to regulatory approval and commercialization is still long, but the support of qualified investors representing a fundamental step in this journey.<\/p>\n\n\n\n<p>The success of this operation also represents a recognition of the value of the Approxima team and the quality of research conducted at the Politecnico di Milano, confirming the excellence of the Italian innovation ecosystem in the life sciences sector.<\/p>\n\n\n<style>.wp-block-kadence-spacer.kt-block-spacer-1085_72a6b2-7e .kt-block-spacer{height:80px;}.wp-block-kadence-spacer.kt-block-spacer-1085_72a6b2-7e .kt-divider{border-top-width:1px;height:1px;border-top-color:#eee;width:80%;border-top-style:solid;}<\/style>\n<div class=\"wp-block-kadence-spacer aligncenter kt-block-spacer-1085_72a6b2-7e\"><div class=\"kt-block-spacer kt-block-spacer-halign-center\"><hr class=\"kt-divider\" \/><\/div><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"conclusions\">Conclusions<\/h2>\n\n\n\n<p>The 7.3 million euro investment round in Approxima represents a success story of Italian innovation in the biomedical sector. The combination of technological excellence, entrepreneurial vision, and professional support has allowed for the successful conclusion of this important operation.<\/p>\n\n\n\n<p>As highlighted by Pietro Ungari: &#8220;It was an experience of enormous value to have contributed with our work to push forward such an important project on the theme of Health.&#8221;&nbsp;<strong>AQ Group<\/strong>, through its company Audit Quality, continues to support the Italian innovation ecosystem, offering high-quality professional services that contribute to the success of strategic operations like this one.<\/p>\n\n\n\n<p>For those looking for a reliable partner in the growth journey of their innovative startup,&nbsp;<strong>AQ Group<\/strong>&nbsp;represents a reference point, thanks to its experience in the sector and its ability to offer complete and personalized support at every stage of business development.<\/p>\n\n\n<style>.wp-block-kadence-spacer.kt-block-spacer-1085_cd783f-10 .kt-block-spacer{height:80px;}.wp-block-kadence-spacer.kt-block-spacer-1085_cd783f-10 .kt-divider{border-top-width:1px;height:1px;border-top-color:#eee;width:80%;border-top-style:solid;}<\/style>\n<div class=\"wp-block-kadence-spacer aligncenter kt-block-spacer-1085_cd783f-10\"><div class=\"kt-block-spacer kt-block-spacer-halign-center\"><hr class=\"kt-divider\" \/><\/div><\/div>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"did-you-know-that\">Did you know that&#8230;?<\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Tricuspid regurgitation<\/strong>&nbsp;affects about 1.6 million people in the United States alone, with a prevalence that increases with age [Source: American Heart Association,&nbsp;<a href=\"https:\/\/www.heart.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.heart.org\/<\/a>].<\/li>\n\n\n\n<li>The&nbsp;<strong>global market for tricuspid valve repair devices<\/strong>&nbsp;is estimated to reach 4.7 billion dollars by 2028 [Source: Global Market Insights,&nbsp;<a href=\"https:\/\/www.gminsights.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.gminsights.com\/<\/a>].<\/li>\n\n\n\n<li><strong>Italian MedTech startups<\/strong>&nbsp;raised over 200 million euros in 2024, with a 30% increase compared to the previous year [Source: Italian Tech Alliance,&nbsp;<a href=\"https:\/\/www.italiantechalliance.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.italiantechalliance.com\/<\/a>].<\/li>\n\n\n\n<li><strong>Minimally invasive procedures for heart diseases<\/strong>&nbsp;can reduce recovery times by up to 70% compared to traditional surgery [Source: European Society of Cardiology,&nbsp;<a href=\"https:\/\/www.escardio.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.escardio.org\/<\/a>].<\/li>\n\n\n\n<li>The&nbsp;<strong>Politecnico di Milano<\/strong>&nbsp;ranks among the top 20 universities in the world for the number of spin-offs in the biomedical sector [Source: Politecnico di Milano,&nbsp;<a href=\"https:\/\/www.polimi.it\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.polimi.it\/<\/a>].<\/li>\n\n\n\n<li><strong>Investments in Life Sciences<\/strong>&nbsp;in Italy exceeded one billion euros in 2024, with a particular concentration in the medical technology sector [Source: AIFI &#8211; Italian Private Equity, Venture Capital and Private Debt Association,&nbsp;<a href=\"https:\/\/www.aifi.it\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.aifi.it\/<\/a>].<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"faq\">FAQ<\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>What is tricuspid regurgitation and what are the symptoms?<\/strong>&nbsp;<br>Tricuspid regurgitation is a condition in which the heart&#8217;s tricuspid valve does not close completely, causing blood to flow backward into the previous heart chamber. Symptoms include fatigue, swelling in the lower limbs, palpitations, and breathing difficulties.<\/li>\n\n\n\n<li><strong>What does the technology developed by Approxima consist of?<\/strong>&nbsp;<br>Approxima has developed a minimally invasive system that allows for the remodeling of the right ventricle through a percutaneous beating-heart procedure, guided by imaging, directly countering the ventricular dilation that causes tricuspid regurgitation.<\/li>\n\n\n\n<li><strong>What are the advantages of a minimally invasive approach compared to traditional surgery?<\/strong>&nbsp;<br>Minimally invasive approaches involve lower operative risks, shorter recovery times, less post-operative pain, and reduced scarring, in addition to allowing the treatment of patients who would not be candidates for traditional surgery.<\/li>\n\n\n\n<li><strong>Who are Approxima&#8217;s main investors?<\/strong>&nbsp;<br>The main investors who participated in the 7.3 million euro round are Enea Tech and Panakes Partners, two Italian investment funds specializing in the life sciences sector.<\/li>\n\n\n\n<li><strong>What are the next steps for Approxima after this investment round?<\/strong>&nbsp;<br>With the funds raised, Approxima will continue preclinical studies to demonstrate the efficacy and safety of the system, preparing to start human clinical trials and begin the regulatory approval process.<\/li>\n\n\n\n<li><strong>What was AQ Group&#8217;s role in the operation?<\/strong>&nbsp;<br>Audit Quality, an AQ Group company, assisted the investment funds in the Tax and Accounting Due Diligence phases and carried out a &#8220;fairness opinion&#8221; on the pre-money value of Approxima, significantly contributing to the success of the operation.<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"sources\">Sources<\/h3>\n\n\n\n<ol class=\"wp-block-list has-small-font-size\">\n<li>Approxima Srl &#8211;&nbsp;<a href=\"https:\/\/www.approxima.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.approxima.com\/<\/a><\/li>\n\n\n\n<li>Politecnico di Milano &#8211;&nbsp;<a href=\"https:\/\/www.polimi.it\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.polimi.it\/<\/a><\/li>\n\n\n\n<li>Enea Tech &#8211;&nbsp;<a href=\"https:\/\/www.eneatech.it\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.eneatech.it\/<\/a><\/li>\n\n\n\n<li>Panakes Partners &#8211;&nbsp;<a href=\"https:\/\/www.panakes.it\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.panakes.it\/<\/a><\/li>\n\n\n\n<li>American Heart Association &#8211;&nbsp;<a href=\"https:\/\/www.heart.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.heart.org\/<\/a><\/li>\n\n\n\n<li>European Society of Cardiology &#8211;&nbsp;<a href=\"https:\/\/www.escardio.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.escardio.org\/<\/a><\/li>\n<\/ol>\n\n","protected":false},"excerpt":{"rendered":"<p>Approxima Srl, a spin-off of the Politecnico di Milano, has concluded a 7.3 million euro Series A round. Audit Quality handled the tax and accounting due diligence.<\/p>\n","protected":false},"author":1,"featured_media":1226,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"yes","_gspb_post_css":"","_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2387","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-senza-categoria"],"acf":[],"taxonomy_info":{"category":[{"value":1,"label":"Senza categoria"}]},"featured_image_src_large":["https:\/\/www.gruppoaq.com\/wp-content\/uploads\/2025\/04\/Gruppo-AQ-Approxima.jpg",721,540,false],"author_info":{"display_name":"adminer","author_link":"#"},"comment_info":0,"category_info":[{"term_id":1,"name":"Senza categoria","slug":"senza-categoria","term_group":0,"term_taxonomy_id":1,"taxonomy":"category","description":"","parent":0,"count":54,"filter":"raw","term_order":"0","cat_ID":1,"category_count":54,"category_description":"","cat_name":"Senza categoria","category_nicename":"senza-categoria","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/www.gruppoaq.com\/en\/wp-json\/wp\/v2\/posts\/2387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gruppoaq.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gruppoaq.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gruppoaq.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gruppoaq.com\/en\/wp-json\/wp\/v2\/comments?post=2387"}],"version-history":[{"count":0,"href":"https:\/\/www.gruppoaq.com\/en\/wp-json\/wp\/v2\/posts\/2387\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.gruppoaq.com\/en\/wp-json\/wp\/v2\/media\/1226"}],"wp:attachment":[{"href":"https:\/\/www.gruppoaq.com\/en\/wp-json\/wp\/v2\/media?parent=2387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gruppoaq.com\/en\/wp-json\/wp\/v2\/categories?post=2387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gruppoaq.com\/en\/wp-json\/wp\/v2\/tags?post=2387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}